{"name":"Kedrion S.p.A.","slug":"kedrion-spa","ticker":"","exchange":"","domain":"kedrionspa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kedbumin 25%","genericName":"Kedbumin 25%","slug":"kedbumin-25","indication":"Hypoproteinemia and hypovolemia in critically ill patients","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Coagadex(R)","genericName":"Coagadex(R)","slug":"coagadex-r","indication":"Congenital Factor X deficiency","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Human Plasminogen","genericName":"Human Plasminogen","slug":"human-plasminogen","indication":"Acute ischemic stroke","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Kedrion IVIG 10%","genericName":"Kedrion IVIG 10%","slug":"kedrion-ivig-10","indication":"Primary immunodeficiency disorders","status":"phase_3"}]}],"pipeline":[{"name":"Kedbumin 25%","genericName":"Kedbumin 25%","slug":"kedbumin-25","phase":"marketed","mechanism":"Kedbumin 25% is a human serum albumin solution that restores and maintains oncotic pressure and serves as a carrier protein for endogenous and exogenous substances in the bloodstream.","indications":["Hypoproteinemia and hypovolemia in critically ill patients","Acute blood loss and hemorrhagic shock","Severe burns","Liver cirrhosis with ascites","Nephrotic syndrome"],"catalyst":""},{"name":"Coagadex(R)","genericName":"Coagadex(R)","slug":"coagadex-r","phase":"phase_3","mechanism":"Coagadex is a recombinant human vitamin K-dependent clotting factor X that replaces deficient or dysfunctional Factor X to restore blood coagulation.","indications":["Congenital Factor X deficiency","Acquired Factor X deficiency"],"catalyst":""},{"name":"Human Plasminogen","genericName":"Human Plasminogen","slug":"human-plasminogen","phase":"phase_2","mechanism":"Activates plasminogen to break down blood clots","indications":["Acute ischemic stroke","Pulmonary embolism"],"catalyst":""},{"name":"Kedrion IVIG 10%","genericName":"Kedrion IVIG 10%","slug":"kedrion-ivig-10","phase":"phase_3","mechanism":"Kedrion IVIG 10% is an intravenous immunoglobulin preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses and neutralize pathogens.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency (e.g., in hematologic malignancies)","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}